Please login to the form below

Not currently logged in
Email:
Password:

crizotinib

This page shows the latest crizotinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Lorviqua receives EC approval for treatment of advanced lung cancer

Pfizer’s Lorviqua receives EC approval for treatment of advanced lung cancer

These are patients whose disease has progressed after receiving alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy, or crizotinib and at least one other ALK TKI. ... Compared to Xalkori (crizotinib), the drug was shown to

Latest news

More from news
Approximately 10 fully matching, plus 61 partially matching documents found.

Latest Intelligence

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    Xalkori: Symptom improvement and quality of life gains add benefit. In the case of Xalkori (crizotinib), Pfizer's product targeting a subsegment of non-small cell lung cancer (NSCLC) in which ... Outcome. Xalkori(crizotinib) in NSCLC. No OS benefit shown

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Difference Collective

Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....